연구동향 분석

혈액응고9인자 분비 유도만능 줄기세포 유래 간세포의 B형 혈우병 치료효과 연구

최준원 2022년

논문상세정보
인용/피인용
' 혈액응고9인자 분비 유도만능 줄기세포 유래 간세포의 B형 혈우병 치료효과 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • B형 혈우병
  • crispr-cas9
  • 간세포 분화
  • 세포 치료제
  • 유도만능줄기세포
  • 유전자 편집
  • 혈액응고인자
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
84 0

0.0%

' 혈액응고9인자 분비 유도만능 줄기세포 유래 간세포의 B형 혈우병 치료효과 연구' 의 참고문헌

  • Zhang, F., Wen, Y., & Guo, X. (2014). CRISPR/Cas9 for genome editing: progress, implications and challenges. Human molecular genetics, 23(R1), R40–R46. https://doi.org/10.1093/hmg/ddu125
    [2014]
  • Yi, S., Yang, Q., Zuo, Y., Li, M., Luo, J., Qin, Z., Zhang, Q., Li, M., Huang, L., Lu, Y., Feng, S., & Fan, X. (2020). A novel missense mutation in F9 gene causes hemophilia B in a family with clinical variability. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 31(2), 121–126. https://doi.org/10.1097/MBC.0000000000000884
  • Wu, Y. M., Kao, C. Y., Huang, Y. J., Yu, I. S., Lee, H. S., Lai, H. S., Lee, P. H., Lin, C. N., & Lin, S. W. (2010). Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice. Cell transplantation, 19(9), 1169–1180.
  • Wang Q, Zhong X, Li Q, Su J, Liu Y, Mo L, Deng H, Yang Y. CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice. Mol Ther Methods Clin Dev. 2020 Jun 30;18:520-531. doi: 10.1016/j.omtm.2020.06.025. PMID: 32775489; PMCID: PMC7393320.
  • Wang D, Zhang G, Gu J, Shao X, Dai Y, Li J, Pan X, Yao S, Xu A, Jin Y, Huang J, Shi Q, Zhu J, Xi X, Chen Z, Chen S. In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A. Haematologica. 2020 Apr;105(4):e175-e179. doi: 10.3324/haematol.2019.219089. Epub 2019 Jul 11. PMID: 31296582; PMCID: PMC7109733.
  • Wall DA, Chan KW. Selection of cord blood unit(s) for transplantation. Bone Marrow Transplant. 2008 Jul;42(1):1-7. doi: 10.1038/bmt.2008.100. Epub 2008 May 12. PMID: 18469873.
  • Török, E., Lutgehetmann, M., Bierwolf, J., Melbeck, S., Düllmann, J., Nashan, B., Ma, P. X., & Pollok, J. M. (2011). Primary human hepatocytes on biodegradable poly(l-lactic acid) matrices: a promising model for improving transplantation efficiency with tissue engineering. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 17(2), 104–114. https://doi.org/10.1002/lt.22200
  • Tuladhar R, Yeu Y, Tyler Piazza J, Tan Z, Rene Clemenceau J, Wu X, Barrett Q, Herbert J, Mathews DH, Kim J, Hyun Hwang T, Lum L. CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat Commun. 2019 Sep 6;10(1):4056. doi: 10.1038/s41467-019-12028-5. PMID: 31492834; PMCID: PMC6731291.
  • The regulation of clotting factors
    Kalafatis M , Egan JO , van 't Veer C , Cawthern KM , Mann KG 7 ( 3 ) :241-80. doi : 10.1615/critreveukargeneexpr.v7.i3.40 . PMID : 9399073 . [1997]
  • Taylor CJ, Bolton EM, Bradley JA. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci. 2011 Aug 12;366(1575):2312-22. doi: 10.1098/rstb.2011.0030. PMID: 21727137; PMCID: PMC3130422.
  • Sidonio RF Jr, Pipe SW, Callaghan MU, Valentino LA, Monahan PE, Croteau SE. Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Rev. 2021 May;47:100759. doi: 10.1016/j.blre.2020.100759. Epub 2020 Nov 10. PMID: 33183859.
  • Sentmanat MF, Peters ST, Florian CP, Connelly JP, Pruett-Miller SM. A Survey of Validation Strategies for CRISPR-Cas9 Editing. Sci Rep. 2018 Jan 17;8(1):888. doi: 10.1038/s41598-018-19441-8. PMID: 29343825; PMCID: PMC5772360.
  • Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler EL, Moliaka YK. Genotype analysis identifies the cause of the "royal disease". Science. 2009 Nov 6;326(5954):817. doi: 10.1126/science.1180660. Epub 2009 Oct 8. PMID: 19815722.
  • Ramaswamy S, Tonnu N, Menon T, Lewis BM, Green KT, Wampler D, Monahan PE, Verma IM. Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX. Cell Rep. 2018 May 1;23(5):1565-1580. doi: 10.1016/j.celrep.2018.03.121. PMID: 29719266; PMCID: PMC5987250.
  • Papapetrou EP, Schambach A. Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Mol Ther. 2016 Apr;24(4):678-84. doi: 10.1038/mt.2016.38. Epub 2016 Feb 12. PMID: 26867951; PMCID: PMC4886940.
  • Pallera AM, Schwartzberg LS. Managing the toxicity of hematopoietic stem cell transplant. J Support Oncol. 2004 May-Jun;2(3):223-37; discussion 237-8, 241, 246-7. PMID: 15328824.
  • Olgasi C, Talmon M, Merlin S, Cucci A, Richaud-Patin Y, Ranaldo G, Colangelo D, Di Scipio F, Berta GN, Borsotti C, Valeri F, Faraldi F, Prat M, Messina M, Schinco P, Lombardo A, Raya A, Follenzi A. Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A. Stem Cell Reports. 2018 Dec 11;11(6):1391-1406. doi: 10.1016/j.stemcr.2018.10.012. Epub 2018 Nov 8. PMID: 30416049; PMCID: PMC6294075.
  • Okamoto, R., Takayama, K., Akita, N., Nagamoto, Y., Hosokawa, D., Iizuka, S., Sakurai, F., Suemizu, H., Ohashi, K., & Mizuguchi, H. (2018). Human iPS Cell-based Liver-like Tissue Engineering at Extrahepatic Sites in Mice as a New Cell Therapy for Hemophilia B. Cell transplantation, 27(2), 299–309. https://doi.org/10.1177/0963689717751734
  • Okamoto R, Takayama K, Akita N, Nagamoto Y, Hosokawa D, Iizuka S, Sakurai F, Suemizu H, Ohashi K, Mizuguchi H. Human iPS Cell-based Liver-like Tissue Engineering at Extrahepatic Sites in Mice as a New Cell Therapy for Hemophilia B. Cell Transplant. 2018 Feb;27(2):299-309. doi: 10.1177/0963689717751734. PMID: 29637813; PMCID: PMC5898695.
  • Ohmori T. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol. 2020 Jan;111(1):31-41. doi: 10.1007/s12185-018-2513-4. Epub 2018 Aug 6. PMID: 30083852.
  • Nienhuis AW, Nathwani AC, Davidoff AM. Gene Therapy for Hemophilia. Mol Ther. 2017 May 3;25(5):1163-1167. doi: 10.1016/j.ymthe.2017.03.033. Epub 2017 Apr 11. PMID: 28411016; PMCID: PMC5417837.
  • Nathwani, A. C., Davidoff, A. M., & Tuddenham, E. (2017). Gene Therapy for Hemophilia. Hematology/oncology clinics of North America, 31(5), 853–868.
    [2017]
  • Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):1-8. doi: 10.1182/hematology.2019000007. PMID: 31808868; PMCID: PMC6913446.
  • Nathwani AC, Davidoff AM, Tuddenham EGD. Gene Therapy for Hemophilia. Hematol Oncol Clin North Am. 2017 Oct;31(5):853-868. doi: 10.1016/j.hoc.2017.06.011. PMID: 28895852.
  • Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW, Gao G. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021 Jan 4;131(1):e143780. doi: 10.1172/JCI143780. PMID: 33393506; PMCID: PMC7773343.
  • Morishige, S., Mizuno, S., Ozawa, H., Nakamura, T., Mazahery, A., Nomura, K., Seki, R., Mouri, F., Osaki, K., Yamamura, K., Okamura, T., & Nagafuji, K. (2020). CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs. International journal of hematology, 111(2), 225–233. https://doi.org/10.1007/s12185-019-02765-0
  • Morishige S, Mizuno S, Ozawa H, Nakamura T, Mazahery A, Nomura K, Seki R, Mouri F, Osaki K, Yamamura K, Okamura T, Nagafuji K. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs. Int J Hematol. 2020 Feb;111(2):225-233. doi: 10.1007/s12185-019-02765-0. Epub 2019 Oct 29. PMID: 31664646.
  • Monahan PE. Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb Haemost. 2015 Jun;13 Suppl 1(0 1):S151-60. doi: 10.1111/jth.12957. PMID: 26149016; PMCID: PMC4712690.
  • Monahan P. E. (2015). Gene therapy in an era of emerging treatment options for hemophilia B. Journal of thrombosis and haemostasis : JTH, 13 Suppl 1(0 1), S151–S160.
    [2015]
  • Mitchell A, Wanczyk H, Jensen T, Finck C. Assessment of iPSC teratogenicity throughout directed differentiation toward an alveolar-like phenotype. Differentiation. 2019 Jan-Feb;105:45-53. doi: 10.1016/j.diff.2019.01.003. Epub 2019 Jan 24. PMID: 30711828.
    [2019]
  • Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013 Jul 4;122(1):23-36. doi: 10.1182/blood-2013-01-306647. Epub 2013 Apr 17. PMID: 23596044; PMCID: PMC3701904.
  • Malik, N., & Rao, M. S. (2013). A review of the methods for human iPSC derivation. Methods in molecular biology (Clifton, N.J.), 997, 23–33. https://doi.org/10.1007/978-1-62703-348-0_3
    [2013]
  • Lyu, C., Shen, J., Wang, R., Gu, H., Zhang, J., Xue, F., Liu, X., Liu, W., Fu, R., Zhang, L., Li, H., Zhang, X., Cheng, T., Yang, R., & Zhang, L. (2018). Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system. Stem cell research & therapy, 9(1), 92. https://doi.org/10.1186/s13287-018-0839-8
  • Lyu C, Shen J, Zhang J, Xue F, Liu X, Liu W, Fu R, Zhang L, Li H, Zhang D, Zhang X, Cheng T, Yang R, Zhang L. The State of Skewed X Chromosome Inactivation is Retained in the Induced Pluripotent Stem Cells from a Female with Hemophilia B. Stem Cells Dev. 2017 Jul 1;26(13):1003-1011. doi: 10.1089/scd.2016.0323. Epub 2017 Mar 22. PMID: 28401797.
  • Lyu C, Shen J, Wang R, Gu H, Zhang J, Xue F, Liu X, Liu W, Fu R, Zhang L, Li H, Zhang X, Cheng T, Yang R, Zhang L. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system. Stem Cell Res Ther. 2018 Apr 6;9(1):92. doi: 10.1186/s13287-018-0839-8. PMID: 29625575; PMCID: PMC5889534.
  • Luce E, Steichen C, Allouche M, Messina A, Heslan JM, Lambert T, Weber A, Nguyen TH, Christophe O, Dubart-Kupperschmitt A. In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model. Hepatology. 2021 Oct 23. doi: 10.1002/hep.32211. Epub ahead of print. PMID: 34687060.
  • Loomans, J. I., Lock, J., Peters, M., Leebeek, F. W., Cnossen, M. H., & Fijnvandraat, K. (2014). Hemofilie [Haemophilia]. Nederlands tijdschrift voor geneeskunde, 158, A7357.
    [2014]
  • Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018). Delivering CRISPR: a review of the challenges and approaches. Drug delivery, 25(1), 1234–1257.
    [2018]
  • Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N, Ranganathan S, Ravinder N, Chesnut JD. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol. 2015 Aug 20;208:44-53. doi: 10.1016/j.jbiotec.2015.04.024. Epub 2015 May 21. PMID: 26003884.
  • Li T, Miller CH, Driggers J, Payne AB, Ellingsen D, Hooper WC. Mutation analysis of a cohort of US patients with hemophilia B. Am J Hematol. 2014 Apr;89(4):375-9. doi: 10.1002/ajh.23645. Epub 2014 Mar 3. PMID: 24375831; PMCID: PMC4504203.
  • Li SJ, Luo Y, Zhang LM, Yang W, Zhang GG. Targeted introduction and effective expression of hFIX at the AAVS1 locus in mesenchymal stem cells. Mol Med Rep. 2017 Mar;15(3):1313-1318. doi: 10.3892/mmr.2017.6131. Epub 2017 Jan 19. PMID: 28112377; PMCID: PMC5367337.
  • Kwon MJ, Yoo KY, Kim HJ, Kim SH. Identification of mutations in the F9 gene including exon deletion by multiplex ligation-dependent probe amplification in 33 unrelated Korean patients with haemophilia B. Haemophilia. 2008 Sep;14(5):1069-75. doi: 10.1111/j.1365-2516.2008.01796.x. Epub 2008 Jul 8. PMID: 18624698.
  • Kumaran V, Benten D, Follenzi A, Joseph B, Sarkar R, Gupta S. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost. 2005 Sep;3(9):2022-31. doi: 10.1111/j.1538-7836.2005.01508.x. PMID: 16102109.
  • Knott, G. J., & Doudna, J. A. (2018). CRISPR-Cas guides the future of genetic engineering. Science (New York, N.Y.), 361(6405), 866–869.
    [2018]
  • Kizilocak, H., & Young, G. (2019). Diagnosis and treatment of hemophilia. Clinical advances in hematology & oncology : H&O, 17(6), 344–351.
    [2019]
  • Kim, T. K., & Eberwine, J. H. (2010). Mammalian cell transfection: the present and the future. Analytical and bioanalytical chemistry, 397(8), 3173–3178. https://doi.org/10.1007/s00216-010-3821-6
    [2010]
  • Khosravi S, Ishii T, Dreissig S, Houben A. Application and prospects of CRISPR/Cas9-based methods to trace defined genomic sequences in living and fixed plant cells. Chromosome Res. 2020 Mar;28(1):7-17. doi: 10.1007/s10577-019-09622-0. Epub 2019 Dec 3. PMID: 31792795.
  • Jiang F, Doudna JA. CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. 2017 May 22;46:505-529. doi: 10.1146/annurev-biophys-062215-010822. Epub 2017 Mar 30. PMID: 28375731.
  • Gupta, S. K., & Shukla, P. (2017). Gene editing for cell engineering: trends and applications. Critical reviews in biotechnology, 37(5), 672–684.
    [2017]
  • Green D. (2006). Coagulation cascade. Hemodialysis international. International Symposium on Home Hemodialysis, 10 Suppl 2, S2–S4. https://doi.org/10.1111/j.1542-4758.2006.00119.x
    [2006]
  • Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost. 2015 Jul;13(7):1184-95. doi: 10.1111/jth.12958. Epub 2015 May 18. PMID: 25851415; PMCID: PMC4496316.
  • George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi: 10.1056/NEJMoa1708538. PMID: 29211678; PMCID: PMC6029626.
  • Genetic analysis of a hemophilia B family with a novel F9 gene mutation : A STROBE-compliant article
    Lv , X. , Li , T. , Li , H. , Liu , H. Y. , Wang , Z. , & Guo , Z. P. 98 ( 21 ) , e15688 . https : //doi.org/10.1097/MD.0000000000015688 [2019]
  • Fomin ME, Togarrati PP, Muench MO. Progress and challenges in the development of a cell-based therapy for hemophilia A. J Thromb Haemost. 2014 Dec;12(12):1954-65. doi: 10.1111/jth.12750. Epub 2014 Oct 31. PMID: 25297648; PMCID: PMC4388483.
  • Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest. 2008 Mar;118(3):935-45. doi: 10.1172/JCI32748. PMID: 18274668; PMCID: PMC2242617.
  • Doudna, J. A., & Charpentier, E. (2014). Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (New York, N.Y.), 346(6213), 1258096.
    [2014]
  • Doetschman, T., & Georgieva, T. (2017). Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease. Circulation research, 120(5), 876–894.
    [2017]
  • Choi JS, Jeong IS, Park YJ, Kim SW. HGF and IL-10 expressing ALB::GFP reporter cells generated from iPSCs show robust anti-fibrotic property in acute fibrotic liver model. Stem Cell Res Ther. 2020 Aug 3;11(1):332. doi: 10.1186/s13287-020-01745-0. PMID: 32746905; PMCID: PMC7398392.
  • Cawthern, K. M., van 't Veer, C., Lock, J. B., DiLorenzo, M. E., Branda, R. F., & Mann, K. G. (1998). Blood coagulation in hemophilia A and hemophilia C. Blood, 91(12), 4581–4592.
    [1998]
  • Castaman, G., & Matino, D. (2019). Hemophilia A and B: molecular and clinical similarities and differences. Haematologica, 104(9), 1702–1709. https://doi.org/10.3324/haematol.2019.221093
    [2019]
  • Boyce, R. W., Dorph-Petersen, K. A., Lyck, L., & Gundersen, H. J. (2010). Design-based stereology: introduction to basic concepts and practical approaches for estimation of cell number. Toxicologic pathology, 38(7), 1011–1025. https://doi.org/10.1177/0192623310385140
    [2010]
  • Bosi A, Bartolozzi B, Guidi S. Allogeneic stem cell transplantation. Transplant Proc. 2005 Jul-Aug;37(6):2667-9. doi: 10.1016/j.transproceed.2005.06.087. PMID: 16182779.
  • Bolton-Maggs, P. H., & Pasi, K. J. (2003). Haemophilias A and B. Lancet (London, England), 361(9371), 1801–1809.
    [2003]
  • Bentz AB, Dossey EK, Rosvall KA. Tissue-specific gene regulation corresponds with seasonal plasticity in female testosterone. Gen Comp Endocrinol. 2019 Jan 1;270:26-34. doi: 10.1016/j.ygcen.2018.10.001. Epub 2018 Oct 3. PMID: 30291863.
  • Batty, P., & Lillicrap, D. (2019). Advances and challenges for hemophilia gene therapy. Human molecular genetics, 28(R1), R95–R101. https://doi.org/10.1093/hmg/ddz157
    [2019]
  • Abad M, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megías D, Domínguez O, Martínez D, Manzanares M, Ortega S, Serrano M. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013 Oct 17;502(7471):340-5. doi: 10.1038/nature12586. Epub 2013 Sep 11. PMID: 24025773.